Astrazeneca PLC cash flow statement

In fiscal 2025, Astrazeneca PLC's operations generated $14.57bn of cash; it spent $2.81bn on capital projects, leaving free cash flow of $11.77bn. It returned $4.97bn in dividends and $521m through buybacks.

Cash flow statement

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Astrazeneca PLC: cash flow statement, annual
Fiscal year	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Cash from operations	3.3	4.1	3.6	2.6	3.0	4.8	6.0	9.8	10.3	11.9	14.6
Stock-based pay	0.2	0.2	0.2	0.2	0.3	0.3	0.6	0.6	0.6	0.7	0.7
Capital spending	1.3	1.4	1.3	1.0	1.0	1.0	1.1	1.1	1.4	1.9	2.8
Free cash flow	2.0	2.7	2.3	1.6	2.0	3.8	4.9	8.7	9.0	9.9	11.8
Free cash flow after stock pay	1.8	2.5	2.0	1.4	1.7	3.6	4.3	8.1	8.4	9.3	11.0
Dividends paid	3.5	3.6	3.5	3.5	3.6	3.6	3.9	4.4	4.5	4.6	5.0
Share buybacks	—	—	—	—	—	—	0.1	—	—	0.1	0.5

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: AZN vs PFE AZN vs MRK AZN vs BMY AZN vs NVO

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Astrazeneca PLC's SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Astrazeneca PLC.